Wednesday, 27 July 2016

Updated events calender

Events
Date
Place
Sponsor
World Hepatitis Day
28th July
Not applicable
World Health Organization
Indian Pharmacovigilance day 2016 conference
29th July
Mumbai
Oviya MedSafe
ICIPS-2016_1st International conference on innovations in pharmaceutical sciences
29th & 30th July
Hyderabad
Guru Nanak Institutions technical Campus School of Pharmacy
National Level Conference On Recent Trends In Pharma Sciences And Life Sciences
28th August
NSIC, Hyderabad
Anveshnana Educational and Research Foundation
FICCI  Healthcare Excellence Awards
31st August
Delhi
FICCI
1st Conference of the Indian Society for the Study of Xenobiotics (SSX®)
1st to 3rd September
IISC Bangalore
Indian Society for Study of Xenobiotics (SSX®)
MDP on Safeguarding Quality of Medicines in Resource – Limited Settings
19th to 23rd
 September
Jaipur
IIHMR University
International Conference On Contemporary Antimicrobial Research 2016
14th to 17th  November
Silchar
Assam University
68th Indian Pharmaceutical Congress
16th to 18th Dec
Vizag
Indian Pharmaceutical Association (IPA)
INNOPHARM 2_International Conference on Bridging Innovations in Pharmaceutical, Medical and Bio Sciences
10th & 11th February 2017
Bhopal
Paramita Health Care Society

Tuesday, 26 July 2016

World Hepatitis Day_28th July 2016


World hepatitis day 2016 would be celebrated by the people all over the world on 28th of July, at Thursday. The theme for this year’s global campaign is ELIMINATION.

History:
In 2010 the World Health Organization made World Hepatitis Day one of only four official disease-specific world health days, to be celebrated each year on the 28th July. Millions of people across the world now take part in World Hepatitis Day, to raise awareness about viral hepatitis, and to call for access to treatment, better prevention programs and government action.

2016 is a pivotal year for viral hepatitis. At the World Health Assembly in May, WHO Member States are set to adopt the first ever Elimination Strategy for Viral Hepatitis, with ambitious targets and a goal to eliminate hepatitis as a public health threat by 2030. This will be the first time national governments sign up and commit to the goal of eliminating viral hepatitis.

Details: http://worldhepatitisday.org/en/about-us



Indian Pharmacovigilance day 2016 conference

Friday, 29 July 2016 - Mumbai, Peninsula Grand Hotel. 


Pharmacovigilance is a domain that involves a variety of stakeholders such as pharmaceutical manufacturers, drug marketers, contract research organizations, regulators, healthcare professionals, subject matter experts and the consumers, among others. India is globally recognized as an important hub for generic drug manufacturing and the Indian pharmaceutical industry has carved a niche for itself in exporting its products to many developed as well as emerging countries. Of late, India is also being seen as a target destination for procurement of support services required for the global pharmaceutical industry, with pharmacovigilance outsourcing having grown to an impressive extent in the past decade.

Simultaneously, newer developments in Indian Pharmacovigilance have occurred which include a requirement for XML-E2B format reporting of ICSRs by the pharmaceutical industry to the Pharmacovigilance Programme of India (PvPI) and the release of the March 8th 2016 dated gazette notification GSR 287 (E) legally mandating pharmacovigilance for all pharmaceutical companies.

At this ripe moment, the task of integrating and streamlining the opinions and expectations of all stakeholders of Indian pharmacovigilance assumes significant relevance. The Indian Pharmacovigilance Day 2016 conference is all set to achieve this formidable goal with immense focus and dedication. During the conference, expert speakers from the industry, health authorities, research bodies, academia and healthcare delivery centres will share their perspectives on the multifaceted outlook of the discipline of pharmacovigilance in India and deliberate on the challenges they expect to face in 2016, with the topics of focus ranging from the current status of clinical trial safety, emerging postmarketing drug safety regulations, different types of pharmacovigilance operations and special scenarios such as ensuring safety of vaccines, biosimilars and medical devices, to name a few.


Details: http://indianpharmacovigilanceday2016.eventify.it/about

Brochure: http://easy-b.it/documents/Brochure_Indian%20PV%20Day_2016.pdf

Monday, 25 July 2016

Abbott in trouble over death of a sales representative


Trouble is brewing at Abbott, India's second-largest drug maker by market share, following an alleged suicide last week by a medical representative in Indore purportedly under pressure to achieve periodic sales targets. Abbott has strongly refuted any role in the employee's death, noting that the deceased was rated among the top performers and had recently qualified for a training certification meant for high performers.

Ashish Awasthi, who was 35, was found dead on a railway track last week. A note recovered from him blamed the company for his death. The incident sparked unrest among Abbott's local field representatives, who have staged a series of demonstrations, demanding adequate compensation for the dead employee's family and better service conditions for field representatives. Members of the union of medical representatives have written to the company's top executives in India and its headquarters in Chicago, highlighting, what they termed, continuous pressure, mental harassment on sales promotion employees and punitive action against field-level staff.

Manish Thacker, secretary of the Indore unit of Madhya Pradesh-Chhattisgarh Medical & Sales Representatives Union, told ET that Abbott is indulging in unethical trade and marketing practices and forcing its sales promotion employees to involve in unethical businesses. In a memorandum to the company, the union, which is affiliated to the Federation of Medical and Sales Representatives' Associations of India, demanded action against the managers responsible for Awasthi's death, adequate compensation to the bereaved family and suitable steps to prevent such incidences in the future. The union pleaded for the formation of a grievance redressal forum.

Awasthi was employed in the neuro life division of Abbott and was a consistent performer, a source said.

In a mailed response to ET, Abbott defended its marketing practices in India, saying the policies, practices and employee training is aligned with applicable laws, regulations and industry codes. "These are cascaded to all our employees when they join the organisation and refreshed through regular training," a spokesperson noted in the mailed statement.

Competition in India's $15-billion pharmaceutical market is fierce and with thousands of players jostling for a share of the market, ethics of marketing practices followed by companies and doctors have come under the scanner frequently. Data from market research agency AIOCD PharmaTrac shows Abbott's pharmaceutical sales at Rs 6,236 crore over the past 12 months, which constituted a 6.2 per cent market share based on moving annual turnover until June.

Source: http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/abbott-in-trouble-over-death-of-a-sales-representative/articleshow/53371880.cms

Drug overcharging case: Supreme Court directs Cipla to pay Rs 175.07 crore


India's Supreme Court had directed drug maker Cipla to deposit a sum of Rs 175.07 crore within six weeks in a case related to alleged overcharging in certain drugs as per the provisions of Drug (Price Control) Order, 1995.

 In a note to stock exchanges late on Friday, Cipla said the writ petitions filed in the Bombay High Court that were pending before Supreme Court have been retransferred to the Bombay High Court for final hearing. The initial order for the deposits was issued by Supreme Court in 2003, which had directed the government to recover 50% of the overcharged amount by the company.

 "The Bombay High Court will now hear these matters on merits," the drug maker said. Cipla and India's drug pricing watchdog have been in a drawn-out legal tussle. The authority has charged Cipla of charging higher prices for a set of drugs than the ceiling price based on a fixed formula.

Source: http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/drug-overcharging-case-supreme-court-directs-cipla-to-pay-rs-175-07-crore/articleshow/53345143.cms

India’s next generation of women leaders in pharma


Economic times recently carried out an interesting article on India's next generation of women leaders. This article covers various women leaders who have made their mark in different fields of life sciences.

1. Namita Thapar 39 CFO, Emcure Pharmaceuticals
2. Zahabiya Khorakiwala 33 Managing Director, Wockhardt Hospitals
3. Tara Singh Vachani 29 CEO & Managing Director - Antara Senior Living
4. Ameera Shah 36, Managing Director, Metropolis Labs
5. Samina Vaziralli 37 Executive Director, Cipla

Link: http://economictimes.indiatimes.com/small-biz/entrepreneurship/meet-indias-next-generation-of-women-leaders-in-pharma/articleshow/53273951.cms

Maha FDA detects cases of steroid-laden creams being sold as OTC drugs


Maharashtra Food and Drug Administration (FDA) has detected cases of leading brands in the country promoting skin creams as OTC drugs for treatment of skin ailments through self-medication in violation of labelling conditions of the Drugs and Cosmetic Rules, 1945

The state regulator is planning to take action against the companies as provisioned under Rule 106 to be read along with Schedule J and Section 18 (6). Stocks worth over Rs.70, 000 have already been seized from retailers in Mumbai alone.

State regulator had earlier seized such steroid-laden creams from different locations in the state and detected two such cases in the past of products UB Fair for men and No Scars cream for women contain steroids like fluocinolon acetonid and mometasone along with skin bleaching agents.

According to a senior FDA official, these skin creams violate the labeling conditions of the Drug Rules and make false claims of making a person fair despite the fact that they are mild steroids. They are recommended to be taken under the direction/ supervision of a senior skin care specialist or dermatologist. Sold under brand names like SuperGlow, My Fair, Skinbrite and ClearSkin, they have Hydroquinone, Tretinoin, Mometasone Furoate which are meant to treat skin disorders based on a doctor’s supervision. 

According to FDA, drugs positioned as fairness creams through companies advertisements have misled the public with false claims on enhancing skin complexion and treatment, a practice that is prohibited, and the use of which could aggravate skin problems.

The products are supposed to be advertised or positioned as a drug which requires a prescription for its use as indicated clinically and not to be sold or to be used as a cosmetic under the provisions of the law.

Maharashtra FDA had also detected cases of illegal sale of steroid-laden creams in the past and cancelled license of a Mumbai based retailer. FDA is also planning to prosecute 3 people involved in illegal sale of Betnovate C cream and Betnovate cream N without a bill worth Rs.40 lakhs in contravention to the provisions of Drugs and Cosmetics Act, 1940.

An FIR has also been filed against the retailer and persons involved in the racket who used to sell these creams with false and misleading claims of enhancing skin complexion despite the fact that it contains a potentially dangerous steroid Betamethasone Valerate which can cause skin cancer.

According to FDA’s recent order, these creams should only be sold only under the prescription of a physician. Meanwhile, government has also considered the proposal to amend a rule that currently exempts steroid based skin creams from being labelled as Schedule H drugs during a recent meet of the Drugs Technical Advisory Board (DTAB) held in Delhi.

The recommendation for such an exemption was in view of the proposal made by the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL).

Mometasone is a potent steroid that can cause acneiform eruption on the face, unwanted hair growth, rosacea (pustular lesions), perioral dermatitis (facial rash) and fixed redness. Other steroids like fluocinolone, hydroquinone and tretinoin are often prescribed for skin diseases like melasma or discoloration but long term usage can cause severe side effects.

Source: http://www.pharmabiz.com/NewsDetails.aspx?aid=96432&sid=1

Thursday, 21 July 2016

FICCI Heal 2016


 
FICCI presents the eighth edition of its annual Healthcare Excellence Awards supported by Quality Council of India on August 31, 2016 from 7:30 pm to 10:00 pm at The Le Meridian, New Delhi.

Indian Healthcare Industry is experiencing new wave of opportunities due to robust domestic demand, rise in innovative healthcare, corporatization of healthcare facilities, influx of medical tourism and governments push towards Make in India.

FICCI Healthcare Excellence Awards 2016 aims at felicitating organizations and individuals for their efforts towards operational excellence, innovatively adopting and inventing technologies and processes for India, and improved healthcare delivery. The FICCI Awards have emerged as the definitive recognition for contribution to healthcare in the country over the years.
 

Details available at: http://www.ficci-heal.com/bro1.pdf

FICCI Whitepaper launch of 'ePharmacy in India - Last mile access of medicines'

At this juncture, when we are moving towards Digital India’ and are encouraging the use of technology in all services, it is important that we do not take any step which could be detrimental to the growth of this channel and restricts the consumers to access to all modes of distribution.

Further to work towards the vision of ‘Digital Health’, e-pharmacy is again an important aspect which needs to be well considered in terms of better outreach to consumers.

To better understand this new channel of distribution and to analyze its challenges and the ways to address them, FICCI has developed a white paper - 'ePharmacy in India - Last mile access of medicines'.

The white paper will be released at a seminar on 25th of July, 2016 at FICCI, New Delhi office in the presence of Government dignitaries, Industry players and other concerned stakeholders.

 

National Level Conference On Recent Trends In Pharma Sciences And Life Sciences

Anveshnana Educational and Research Foundation organizing eminent Pharmaceutical conferences welcomes you to attend the National Level Pharmacy conference to be held during August 28th, 2016 in NSIC. Ecil focuses on the advancements in pharmacy and Quality risk management. The field of Pharmacy is growing rapidly and its development is making tremendous impacts in Global world of pharmaceuticals. Emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of International Pharmacy conference is “Innovations in exertions of Pharmacy”.
 
Venue: NSIC ( The National Small Industries Corp Ltd. ) Near Radhika X Roads, ECIL, Hyderabad, 500 062. 
 
Early Bird Registration
01st August 2016
Approval Notification
26th August 2016
Final Paper Submission
26th August 2016
Last Date of Registration
26th August 2016
Date of Conference
28th August 2016

Guidelines for Opening of Jan Aushadhi Store for different category

The guidelines for Opening of Jan Aushadhi Store for different category are revised:
For - Individuals Entrepreneurs/Unemployed Pharmacists/Doctors/Registered Medical Practitoners
For - NGO Hospitals/Charitable Institutions/Private Hospitals/Trust/Societies/Self help Group
For - State Government Nominated Agencies
For - Mobile Jan Aushadhi Medical Store Scheme
 
The guidelines are available at: http://janaushadhi.gov.in/guidelines.html

International symposium on pharmacogenomics and pharmacoeconomics in healthcare system

 
 

WHO report sounds alarm on ‘doctors’ in India


Almost one-third (31 per cent) of those who claimed to be allopathic doctors in 2001 were educated only up to the secondary school level and 57 per cent did not have any medical qualification, a recent WHO report found, ringing the alarm bells on India’s healthcare workforce.

The situation was far worse in rural India, where just 18.8 per cent of allopathic doctors had a medical qualification, the study titled ‘The Health Workforce in India’, published in June 2016, revealed.

Speaking to The Hindu, Dr. Reena Nayyar, Secretary of the Medical Council of India (MCI), said, “I don’t think this report has officially come to the MCI yet. But in general, any person practising allopathic medicine who does not have a registered medical qualification comes under quackery.” 

Interestingly, female healthcare workers – 38 per cent of the total – were found to be more educated and medically qualified than their male counterparts.
For instance, among allopathic doctors, 67 per cent of females had a medical qualification compared to 38 per cent of males.

The data for each district in the country from the 2001 census were specially extracted for this study, which provided a comprehensive picture of health workers in each district.

Researchers hoped that a similar study was repeated with data from Census 2011, which was not yet available.

The study revealed that the density of all doctors — allopathic, ayurvedic, homoeopathic and unani — at the national level was 80 doctors per lakh population compared to 130 in China.
Ignoring those who don’t have a medical qualification, the number for India fell to 36 doctors per lakh population. As for nurses and midwives, India had 61 workers per lakh population compared to 96 in China. The number reduced tenfold to 6 per lakh population, if only those with a medical qualification were considered.

Health workers
The study found substantial variation in the density of health workers across States and districts. For instance, Kerala had 38.4 per cent of the country’s medically qualified nurses but constituted only 3.1 per cent of the total population. Similarly, West Bengal had 30.6 per cent of all homoeopathic doctors in the country but only 7.8% of the population. Better-off States seemed to afford more doctors plus nurses per capita, the study noted.

District-wise, the inequalities were massive. The density of allopathic doctors with any level of education in the lowest 30 districts — half of which were in north-eastern States and the other in central States — was a little over 9.4 per lakh of the population whereas, in the highest 30 districts, it was 159 per lakh of population, it said. 

Details: http://www.thehindu.com/data/who-report-sounds-alarm-on-doctors-in-india/article8862753.ece

Friday, 15 July 2016

MDP on Safeguarding Quality of Medicines in Resource – Limited Settings


IIHMR University, Jaipur is organizing Management development program on Safeguarding Quality of Medicines in Resource – Limited Settings on 19th to 23rd September 2016.

Details available at:

OBJECTIVES OF THE PROGRAM
The Specific objectives of the program are:-
• To provide technical guidance for establishing a robust quality assurance framework for ensuring good quality of medicines in spite of limited human and financial resources;
• To comprehend key concepts and principles pertaining to quality of medicines;
• To underline the key issues and challenges affecting the quality of medicines in the existing healthcare systems and identifying the ways to mitigate the quality issues

PROGRAM CONTENTS
• Significance of quality assurance & quality control activities in ensuring quality of medicines (Examples and case studies related to HIV, TB, Malaria, Antibiotic, Reproductive health commodities will be discussed);
• Three-tier testing approach-a cost effective approach to medicines quality monitoring;
• Combating substandard & counterfeit medicines;
• Non invasive techniques and rapid detection techniques for determining drug quality;
• Maintaining product quality throughout the supply chain (special emphasis on Procurement, storage and distribution aspects);
• Importance of national medicine policy;
• Complying with Good Manufacturing Practices (GMP) in resource limited countries;
• WHO prequalification program;
• Role of Medicine Regulatory Authorities and Pharmacovigilance framework;
• Ensuring quality of the donated medicines.

Thursday, 14 July 2016

Master class on 'Leadership, Influence and Decision Making'​


The admission time is here. If you are planning for an MBA course in near future, this one is for you. 

Become a better negotiator, attend the Master class on 'Leadership, Influence and Decision Making'​ by Professor Dishan Kamdar on July 24 in Mumbai. Request an invitation for the session. *Participation is by invitation only.

The form is available at http://isbadmissions.isb.edu/master-class-mumbai

This session will be beneficial to everyone whose work involves negotiating with subordinates, peers, superiors and vendors. Those who seek to better understand the strengths and weaknesses of their own negotiation style and strategic habits, improve their own negotiation performance and enhance the quality of their negotiated settlements will benefit from this class.

About the speaker:

Prof Kamdar is a Senior Faculty and the Deputy Dean at the Indian School of Business. 
He holds a PhD and an MSc in Management from the National University of Singapore. His research interests include contextual work performance, organisational citizenship behaviours (OCB), and relationships between group composition and group performance. 

Prof Kamdar has published several research papers in the Journal of Applied Psychology on leadership; effects of personality and workplace social exchange in predicting OCB and task performance, and effects of role perception on interpersonal helping  and taking charge.
He has also co-authored a book chapter in a Handbook on Organisational Citizenship Behaviour titled ‘A review of Good Soldier Activity in Organisations.'

See his profile here: http://www.isb.edu/faculty-research/faculty/directory/kamdar-dishan

Moisture-impermeable polymer using graphene for pharmaceutical packaging


Use of graphene will also bring down the cost of packaging drugs, food and electronic items

Scientists from the Indian Institute of Science (IISc), Bengaluru, are close to field-testing an alternative to plastic packaging for the electronics and pharmaceutical industry, which can increase the shelf-life of electronics, drugs and subsequently bring down costs. Prof Srinivasan Raghavan from the Centre for Nano Science and Engineering and Prof Praveen C Ramamurthy from the Department of Materials Engineering are using graphene to make paper impermeable, that is moisture-proof, which will in turn help replace plastic packaging. A prototype has already been made.

While flexible, transparent and moisture impermeable materials are critical for packaging applications in electronic, food and pharmaceutical industries, the average plastics or polymers are, not water proof enough, thereby reducing the lifetime of electronics and medicines.

"For the packaging industry, it will be significant, especially for pharma. Medicines have expiry dates and major issue is due to packaging failure, as a result of which moisture and oxygen seeps into the packets. So drugs interact with the oxygen and moisture and consequently fail. Hence, if there is better packing, this will increase the lifetime or expiration date of drugs by several more years, automatically reducing the cost of medicines. The field tests are expected to start within a month," Prof Ramamurthy told Bangalore Mirror.

The team says that if realised, it could be an invention that parallels the invention of plastics themselves atleast as far as packaging goes, with particular respect to current packaging used for medicines and electronics.

As a step in this direction, the researchers have developed and demonstrated moisture-impermeable polymer using graphene. This, according to the team, reduces its water vapour transmission rate by up to a million fold. The team has applied for a patent and the findings have been published in ACS Nano journal.

According to Gubbi Labs, which is a private research collective, the new organic polymer is expected to address the challenge of "permeation of atmospheric water vapour into flexible organic electronic devices, thus increasing its active lifetime and improving performance."

This whole project started when Prof Raghavan told Prof Ramamurthy that they make graphene in their lab and it was impermeable even to helium and that they were attempting to make paper impermeable. "This is when I suggested that we first try it on plastics as he was working on making plastics, which are supposedly waterproof and even more impermeable. The next week we had the first result and soon the patent was submitted," added Prof Raghavan.